Beam Therapeutics Inc. (NASDAQ:BEAM) has secured U.S. FDA orphan drug designation for BEAM-302, its pioneering genetic ...

The Cambridge, Mass.-based biotechnology company's drug, BEAM-302, is a liver-targeting lipid nanoparticle formulation that is designed to correct for a mutation in patients with alpha-1 antitrypsin ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration ...

(Alliance News) - Nuformix PLC on Thursday said its lead programme, NXP002, has been granted orphan drug designation by the European Medicines Agency for the treatment of idiopathic pulmonary fibrosis ...

“The first patient in Prescient’s Phase 2a study has been dosed at the Linear Clinical Research site in Perth, under the care ...

Fast Track Designation is given to drugs that are intended to treat serious conditions and or fill an unmet medical need.

Opening of Japan’s first clinical trial site for ACTION3 triggers the first development milestone payment of ¥400 million ...

Bell Potter currently has a buy rating and $63.00 price target on its shares. This suggests that upside of 80% is possible ...

These groundbreaking treatments offer new hope for patients to live longer and healthier lives. But ensuring patients benefit ...

Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined ...

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and ...